Europe hedges its bets as Starmer courts China, war tech backfires in Ukraine, AstraZeneca doubles down, and Denmark asserts ...

Biotechnology demands a particular tolerance for the unknown. Drug development timelines stretch across years, clinical trials produce unexpected results ...

An Ontario court denied a hedge fund’s request to adjourn and delay a company’s annual meeting, amid allegations that the ...

ASX life science stocks have lobbed a flood of quarterly reports ahead of Friday's cut-off – and some of the news is pretty ...

Atara Biotherapeutics in Thousand Oaks is seeking approval for a new cancer treatment. It's a life and death matter for ...

Biotech data visualization is often static and fragmented, limiting the ability to see integrated patient journeys and ...

Healthcare stocks rebounded in 2025. These three healthcare growth stocks offer exposure to innovation beyond traditional ...

We’re hoping to see more early-stage funding in 2026 to help newer companies get off the ground. The public market, especially IPOs, has been a bit slow, with only 11 companies going public in 2025, ...

Patent rights offer a legally recognised exclusive opportunity to startups to commercialise their inventions. They serve as a ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing ...

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived ...